Clinical Study On Efficacy And Safety Of Decitabine Sequential Or Simultaneous With "3+7" Regimenin In The Treatment Of Patients With Newly Diagnosed Acute Myeloid Leukemia

Objective:To compare the clinical efficacy and safety among decitabine combined standard induction regimen at different time points in the treatment of patients with newly diagosed acute myeloid leukemia(AML).Methods:We retrospectively analyzed the clinical data of 45 newly diagnosed patients with AML admitted to our hospital from January 2012 to March 2018.All patients were classfied by 2016 WHO classification of acute leukemia.Among them,29 patients receiving decitabine incombined with with“3+7”regimen in a sequential manner,16 cases of simultaneous chemotherapy regimen,treatment effects and adverse reactions were analyzed,statistical analysis was conducted by SPSS19.0.Results:1)There was no differences in basic characteristics in two goups(P>0.05).2)Overall respond rate in all patients was 75.56%,complete remission was55.6%;ORR in decitabine sequential or simultaneous with“3+7”regimenin was75.9%,75.0% respectively(P=0.842),sequential regimenin 58.6% achieved CR,simultaneous regimenin was 50%.3)The average follow-up time was 8 months,the overall survial and relapse-free survial did not show difference.4)In the sequential group,granulation period was significantly prolonged,the incidence of perianal/gastrointestinal infection was increased,but there were no statistically significant differences in hemoglobin and thrombocytopenia.Conclusion:Whenever in sequential group or simultaneous group,the induction efficacy of decitabine combined with chemotherapy were similar,but the simultaneous group had better safety,the duration of myelosuppression was shorter,mainly manifested as shortening of the granulosis period,less blood cell infusion,and a lower incidence of infection.